Determining Individualized Cancer Therapy in Pancreatic Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Targeted Therapy.
- Who it may be relevant to
- Registry conditions: Pancreatic Neoplasms. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Profile-Related Evidence Determining Individualized Cancer Therapy in Pancreatic Cancer (PREDICT-PANC)
Overview
This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patients. Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well molecular testing might predicts response to therapy. Patient demographic and outcome parameters to be evaluated include, but are not limited to, tumor response, time to treatment failure, patient survival, and toxicity.
Interventions
- Other Targeted Therapy
Approved interventions based on the subject's genomic profile will be provided to investigators for consideration for anti-tumor therapy.
Primary outcome measures
- Number of Subjects Receiving Targeted Therapy [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Age ≥18 years.
- Pathologically confirmed pancreatic cancer.
- Ability to understand a written informed consent document and the willingness to sign it
Exclusion criteria
- Age <18 years.
- Primary cancer diagnosis other than pancreatic cancer.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- Froedtert Hospital and the Medical College of Wisconsin — Milwaukee
Identifiers
NCT: NCT05914987 · PRO00048019